CDSCO panel nod to Biological E to conduct Phase II trial of vaccine for 6- 8 weeks-old infants
Advertisement
Reviewing the Phase I clinical trial report, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the vaccine maker Biological E to conduct a Phase II clinical trial of Diphtheria, Tetanus, Pertussis (Whole cell), Hepatitis B (rDNA), inactivated Poliomyelitis and Haemophilus influenzae Type b Conjugate Vaccine (Adsorbed) for 6- 8 weeks-old infants.
This came after the vaccine maker Biological E presented its proposal for the conduct of a Phase II clinical trial in 6- 8 weeks-old infants along with a Phase I clinical trial report.
For the full story, check out the link given below:
Biological E Gets CDSCO Panel Nod To Study Vaccine For 6- 8 Weeks Old Infants
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.